Guggenheim Maintains Neutral on Amgen, Raises Price Target to $351

Benzinga Newsdesk www.benzinga.com Positive 58.1%

Neg 0% Neu 0% Pos 58.1%

Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $347 to $351.